Adult respiratory distress syndrome (ARDS) is a rare but important complication of blood transfusion because it has a mortality rate of 50-60%. ARDS is characterised by noncardiogenic pulmonary oedema and is often associated with major trauma and/or sepsis. Clinical features include dyspnoea, tachypnoea, chills and extensive crepitations. The pathogenesis has not been elucidated completely and a number of hypotheses have been proposed. Factors which have been implicated include neutrophil sequestration and complement activation, macrophages, metabolites of the arachidonic acid cascade and cytokines, all of which contribute to the amplification of the inflammatory process. In particular, leucoagglutinins have been implicated with blood transfusions. Treatment is generally supportive as specific therapeutic strategies remain largely unproven.
pulmonary bypass, transfusions and transplantation and (c) systemic organ function which examines the acid base status; renal, hepatic, bone marrow, cardiovascular and central nervous system function. 4 The overall incidence of ARDS was 150,000 per annum in the USA in 1977. The death rate is estimated to be 50-60070.
Clinical features of ARDS
The onset of respiratory distress occurs from as quickly as several minutes to up to 40 hours post transfusion with most occurring at 4 to 8 hours. 5 Symptoms include dyspnoea, cough, chills and fever. Signs include tachycardia, tachypnoea, cyanosis and both crepitations and wheeze. The chest X-ray usually reveals extensive bilateral, interstitial alveolar infiltrates. The pulmonary capillary wedge pressure and cardiac output are normal. However, pulmonary arterial pressure may increase. 6 Two recent reviews of ARDS post transfusion have attempted to quantify the incidence and aetiology of transfusion related ARDS. A very large study from New Zealand by Henderson et al documented 1,500 transfusion reactions between 1981 and 1987 from a total of 440,000 units of blood products. There were five cases of pulmonary oedema (incidence of 0.(01070) from which there were no deaths. Sazama 7 described 256 deaths related to transfusion from 1976 to 1985 in the USA. Thirty-nine were due to acute pulmonary injury. Of these, thirty-one were due to pulmonary oedema and eight were due to anaphylaxis. The amount of transfused product varied from 30 ml to 3 litres. Platelets were implicated in Anaesthesia and Intensive Care, Vol. 21, No. I, February, 1993 eleven cases, red blood cells in ten cases, plasma in two cases, white cells in two cases, whole blood in one case and plasmapheresis in four. Overall there were 100 million units of blood products used which led to the thirty-nine deaths, i.e. a mortality incidence of 0.0004070. There are no other authoritative large studies available at present.
PATHOGENESIS

Current concepts
The mechanisms involved in the development of ARDS are complex. Considerable early evidence supported a major role for complement activation and neutrophil influx into the lung causing significant damage to the pulmonary microvasculature. 8 This hypothesis proposed that an underlying disease process such as sepsis caused long-term or excessive complement activation. Active complement components (C3A C5A) which are potent neutrophil chemotactic factors have been demonstrated in several studies. 9 11 Pulmonary sequestration of neutrophils then leads to an associated systemic neutropenia. Hammerschmidt 10 claimed that complement activation was important in the pathogenesis of ARDS and noted polymorphonuclear aggregating activity correlated with the development of ARDS. The measurement of C5A was also a useful predictor of ARDS. Another study by Robinson et alii found C5A in bronchoalveolar lavage fluid in patients with ARDS demonstrating the presence of complement activation and suggesting that C5A may account for the influx of neutrophils into the lungs whilst increasing their adhesiveness leading to deposition as microemboli in the lungs. There is also evidence of activation of neutrophils within the lung. [12] [13] [14] Weiland et al" found a high direct correlation between the alveolar-arterial oxygen difference and the percentage of neutrophils in bronchoalveolar lavage fluids in ARDS.
The hypothesis that neurophils are essential for the pathogenesis of acute lung injury is supported by several studies. Activated neutrophils can produce endothelial cell damage. Zimmerman et al '3 found that granulocytes were functionally and metabolically active in patients with ARDS and were more likely to release active oxygen species, proteolytic enzymes and products of the arachidonic acid cascade which potentially could injure the pulmonary vascular bed and cause alveolitis. Experimentally induced neutrophil depletion appears to attenuate vascular permeability and changes induced by endotoxaemia and hypoxaemia. 15 Other studies have found conflicting evidence. Duchateau et al 9 showed C5A-like activity was found in patients at risk of ARDS but it did not appear to Anaesthesia and Intensive Care, Vol. 21, No. I, February, 1993 be a real predictor of ARDS occurrence in these patients, and they concluded that the development of ARDS may involve factors other than complement activation. Similarly complement depletion in sheep failed to prevent endotoxin induced lung injury. The occurrence of ARDS in neutropenic patients following chemotherapy revealed the failure of neutropenia to prevent ARDS and challenged the concept of neutrophil involvement. 16 Not all studies confirm the presence of functionally active neutrophils. '7 Platelet Abnormalities: A variety of substances, such as endotoxin during sepsis, may recruit platelets to the lung where they aggregate and release mediators including serotonin (one of the most potent vasoconstrictors in humans), which increase pulmonary artery pressure. Platelets may promote neutrophilinduced pulmonary damage by releasing agents that increase neutrophil chemotaxis, adherence, phagocytosis and aggregation. There is clinical evidence that platelets sequester in the pulmonary circulation. Thrombocytopenia has been noted in up to 50070 of ARDS and tends to parallel the degree of hypoxaemia. Although studies reveal that there is sequestration of platelets, however, it is unclear whether they are purely localised to the site as a secondary event or are active participants. 18 Intravascular microembolisation of platelets occurs, which could lead to transient mild pulmonary oedema and focal endothelial damage due to the release of vasoactive substances mediating membrane permeability. A causative role for platelets in generating this damage has not been demonstrated clearly.
Evidence from in vitro studies 19 suggests that platelets can cause pulmonary hypertension via a release of vasoactive substances such as thromboxane A2 (TXA2). The ability of TXA2 to generate a pulmonary pressor response is well supported in the literature. However, the source of the TXA2 in the pulmonary circulation is unclear as neutrophils, macrophages and injured endothelial cells can also generate TXA2. There are several conflicting studies on the relative importance of platelets in the development of hypertension. Stimulated platelets release metabolites of arachidonic acid which are further metabolised by neutrophils generating leukotrienes in a much larger concentration than by polymorphs alone. Damaged endothelial cells release TXA2 and platelet activating factor (PAF), attracting additional platelets by which they may not only cause further damage but also produce growth factors required by the endothelium to sustain injury and generate repair, e.g. platelet derived growth factor (PDGF), and this may stimulate excess fibroblast deposition of collagen with subsequent formation of pulmonary fibrosis.
The Role of Endotoxin: In 1974 Brigham et a1 20 found that infusion of pseudomonas into sheep lymphatics caused a prolonged increase in lung vessel permeability to protein and demonstrated marked increases in lymph flow without the development of pulmonary oedema. It was concluded that lung lymphatics had a high capacity mechanism for removing excess fluid due to vessel wall structural changes due to endotoxin. In 1985 endotoxaemia was demonstrated to induce neutrophil influx into the air spaces of rats at 24 hours. 21 Endotoxin primes neutrophils and phagocytes to emit an amplified superoxide response to agents that activate NADPH oxidase. Thus, endotoxin priming leads to progressive amplification of complement-mediated responses. It was observed that the combination of circulating endotoxin and complement activation more accurately predicted the onset of ARDS in patients, while complement activation alone was not specific. 22 A study by Brigham et al found that endotoxin may cause direct endothelial cell damage and activate endothelial cells to release toxic metabolites of oxygen. 23 Even in apparently nonimmunosuppressed patients it is clear that ongoing infection is an extremely important factor differentiating patients with spontaneously resolving ARDS from those with progressively fatal ARDS.24 Endotoxin can cause structural damage by sequestration and degranulation of neutrophils-macrophages, contributed by release of proteolytic enzymes and interleukin 1 (ILl) attracting more polymorphs. Functionally there are changes in both the airways and lung mechanics: there is an increased airway reactivity after ARDS and increased resistance to airflow and a decrease in dynamic compliance. An increased pulmonary vascular resistance has been measured in sheep in the presence of a normal cardiac output and despite the loss of vasoconstrictive response to hypoxia. 25 Macrophages: Macrophages have emerged as another route of injury. They are central to phagocytosis and in the process release larger amounts of potentially injurious substances including proteases, toxic oxygen radicals, products of arachidonic acid metabolism and cytokines e.g. Interleukin 1 (ILl), TNF. 26 It has been noted that the NADPH oxidase production from macro phages is stimulated by endotoxin. Macrophages have a longer lifespan than neutrophils, and therefore chemotherapeutic drugs which cause neutropenia are less likely to cause a monocytopenia as quickly. Macrophages contribute to the regulation of the immune system, unlike neutrophils. Cytokines: Cytokines have been recognised increasingly as having importance in the pathogenesis of ARDS particularly tumour necrosis factor (TNF). TNF is a monokine derived from mononuclear cells and is released in response to gram-negative endotoxin and gram-positive bacteria, IL2 and other mediators. TNF has emerged as a mediator of general inflammation and regulates aspects of endotoxin induced ARDS. Its effects on neutrophils include increased chemotaxis, phagocytosis, leukostasis and adhesiveness to endothelial cells with neutrophil degranulation. 27 After TNF infusion there is neutrophil sequestration in the lung, haemorrhage, oedema of many organs including the kidney, gut and lung (i.e. shock). TNF is directly toxic to vascular endothelial cells and is an endogenous pyrogen. 28 TNF in vitro (used in guinea pigs) caused peripheral neutropenia, systemic hypotension, increased pulmonary permeability and pulmonary oedema suggesting that TNF could contribute to the pathogenesis of acute lung injury due to sepsis. 29 LPS, a lipopolysaccahride extracted endotoxin injected into rabbits, led to TNF production and development of hypotension, focal hepatic necrosis and intravascular fibrin deposition and death. Prior infusion of anti TNF antibody provided significant protection. 30 The strongest evidence implicating TNF as a principal mediator in ARDS is that antiendotoxin antibody prevented the sequence of endotoxic or gram negative septic shock. This suggests that septic shock and ARDS are not due solely to the direct effects of bacterial toxin but rather represent the effects of excess stimulation of TNF biosynthesis. 31 Prostaglandins and Leukotrienes: These are without question involved in the development of hypoxaemia and ARDS, but they do not appear, however, to be a major factor in the development of increased vascular permeability. Thromboxane A2 (TXA2) and leukotrienes are probably the most important of the arachidonic acid metabolites. TXA2 causes pulmonary hypertension and decreased pulmonary compliance after injection of endotoxin with subsequent complement activation. The leukotrienes LTC4, LTD4 and LTE4 (slow releasing substances of anaphylaxis) can cause changes in lung mechanics such as airway constriction and pulmonary vasoconstriction and can also increase pulmonary vascular permeability. LTD4 in particular is associated with white cell aggregation and adherence to cells. Lipooxygenase products of arachidonic acid metabolism such as LTB4, LTC4 and LTD4 can all cause oedema and LTC4 and LTD4 may do this directly without the presence of neutrophi Is. 32 These are also generated by macrophages and leucocytes as well as pulmonary endothelial and epithelial cells after stimulation. changes in lung mechanics caused by endotoxaemia. They found that these changes were most marked at one hour following endotoxaemia, paralleling severe pulmonary hypertension which eventually returned to normal. This suggests that cyclooxygenase products are probably important in the early changes in lung mechanics and hemodynamics but not in the late phase which includes increased pulmonary capillary permeability. 33 Mediators other than complement: These include toxic oxygen radicals such as superoxide (02-), hydrogen peroxide (H202) and hydroxyl radical (OH-) which are produced by neutrophils, macrophages and platelets. Their production may be contributed to by high inspired oxygen concentration and reperfusion of hypoxic tissues which may lead to an additional oxidant burden. This creates an oxidative milieu and the release of enzymes which are destructive to lung tissue. The antiprotease balance is disturbed in ARDS leading to the destruction of the architectural integrity of the lung. Studies reveal that oxidants released from neutrophils lead to the inactivation of antiproteases. 34
ARDS SECONDARY TO BLOOD TRANSFUSION
Until now the pathogenesis of ARDS has been discussed in general terms. Regardless of the specific causes, the way(s) in which the lung responds to insult are similar. The mechanisms involved in the causation of ARDS are not known and investigations have been limited by the rarity of its occurrence. Some studies have established a role for leucoagglutinins as a principal cause. Reviewing the reproduction of transfusionrelated lung injury in a lung model by Sega et al demonstrated the importance of leucoagglutinin antibodies with neutrophil and complement activation. 5 In this study the reaction was dependant on 5b expressing granulocytes and antibody of anti 5b specificity. Complement was not necessary for initiation to occur in all cases. Current belief is that ARDS is due to the passive transference of donor antibodies against leucocytes and this has been demonstrated in a number of studies. Gans et al 6 noted two cases where there was passive transfusion of leucocyte antibodies from donor to recipient. Rarely there may be presence of leucocyte antibodies in the recipient's serum. In one of these cases there were polyspecific HLA antibodies against lymphocytes, platelets and granulocytes of the donor's blood found in the patient's serum, but no antibodies against leucocytes were detected in the donor's serum. Rarely there may be granulocyte-specific antibodies. acute lung injury associated with passive transfer of anti-leucocyte antibodies, leucoagglutinins were found in the donors' whole blood which when transfused caused the development of non-cardiogenic pulmonary oedema. In four of these five patients, antibodies of HLA specificity were found, and in one it was a non-HLA leucoagglutinin antibody. However, all cases had donor antibody cytotoxic to recipient lymphocytes, It is felt that this leucocyte antibody interaction leads to the activation of neutrophils and release of destructive enzymes. HLA antibodies are present in the plasma of many donors but they do not cause reactions. The reason ARDS occurs is not clear and it may be due to other synergistic effects including both the clinical status of the patient and the characteristics of the antibodies and antigens involved. Prevention of this is difficult as no test has confidently identified the specific antibodies.
MANAGEMENT
Management is largely supportive, i.e. mechanical ventilation and PEEP to improve oxygenation. Alternative forms of oxygenation include extracorporeal membrane oxygenation (ECMO) but there has been no improvement in the survival in studies so far.
Pharmacological therapies
Corticosteroids: Several laboratory studies have suggested that corticosteroids inhibit the mechanisms involved in inducing ARDS. The clinical use of corticosteroids in ARDS remains subject to debate. Investigations have found no difference in the survival rates of treated and untreated patients. Bone et al 37 evaluated the use of high-dose methylprednisolone in a multicentre randomised double-blind placebo controlled trial involving 382 patients with either sepsis syndrome or septic shock. Corticosteroids were given within two hours of the diagnosis. Treatment did not affect the incidence of shock or its reversal. Overall mortality was 34070 in the steroid treated group versus 25% in the placebo treated group. Could steroids affect pulmonary function or outcome if given after ARDS is established? This was addressed by Bernard et al. 38 There was no statistically significant difference between the two groups. In summary, steroids do not prevent the development of ARDS or hasten its reversal or lessen mortality in patients with the sepsis syndrome.
Prostaglandin El (PGE1): PGE 1 inhibits platelet aggregation, neutrophil chemotaxis and prevents release of oxygen radicals and proteolytic enzymes from neutrophils. Early results using PGE 1 infusion appeared promising. Holcroft et al 39 reported a nonsignificant trend towards improved survival in an encouraging pilot study; however, the numbers were small and the results did not reach statistical significance. Bone et al'o evaluated a much larger study of 100 patients and the trend here suggested a worse outcome with PGEI treatment. However this also was not statistically significant and the issue remains unresolved.
Surfactant: Surfactant is a lipoprotein that decreases surface tension and increases lung compliance. The benefits of surfactant replacement have been observed in the neonatal respiratory distress syndrome. Trials of surfactant in ARDS are in progress and only preliminary data are available. Currently it cannot be recommended.
Antiendotoxin Antibodies: Only preliminary results of human trials of monoclonal antibodies are available. Bernard et al 41 evaluated monoclonal IgM antibody in 486 patients in a double-blind randomised control study. Bernard et al reported a decreased mortality rate from gram-negative sepsis in patients not in shock, but it had no effect in those already in shock. The effect of such antibodies on the incidence and outcome of ARDS is unknown at present.
Non-Steroidal Anti-Inflammatory Drugs-NSAIDS: In a preliminary study of patients with sepsis syndrome,42 patients were given 800 mg of ibuprofen or placebo for three doses. Shock was reversed within forty-eight hours in 43070 of the placebo group compared with 88070 in the treated group but there was no improvement in oxygenation. There did appear to be improvement however in cardiodynamic performance. Further trials are required to confirm these findings.
Anti Tumour Necrosis Factor Antibody: No human studies have been performed to date. In vitro studies have suggested benefit, i.e. prevention of end-organ damage following sepsis, but it does not appear to improve mortality rate.
Pentoxifylline: Pentoxifylline is a phosphodiesterase inhibitor which raises CAMP levels within neutrophils and inhibits many of the cells inflammatory functions. There have been no human studies to date and thus it remains of unproven benefit. In guinea pigs it demonstrated a protective effect against TNF induced lung injury. It appeared to prevent hypotension, pulmonary oedema and decreased pulmonary infiltration in the lung and lung albumin accumulation caused by TNF induced lung injury.'3 The mechanism of action of pentoxifylline is not clear and it is regarded at present as being of potential benefit only.
CONCLUSION
Although ARDS is a well recognised, albeit infrequent, hazard following blood transfusion, it is important to be aware of the possibility of its occurrence. The pathogenesis of this complex syndrome appears to involve multiple factors interrelating with each other in a manner not well understood. Further research should be directed towards prevention and elucidation of the underlying causes.
